|Year : 2020 | Volume
| Issue : 4 | Page : 213-219
The enhancement apoptosis of osteosarcoma mesenchymal stem cells co-cultivation with peripheral blood mononuclear cells sensitized by secretome and granulocyte macrophage colony-stimulating factor
Ferdiansyah Mahyudin1, Hizbillah Yazid1, Mouli Edward1, Mohammad Hardian Basuki1, Yunus Abdul Bari1, Fedik Abdul Rantam2
1 Orthopedic and Traumatology Department, Faculty of Medicine, Dr Soetomo General Hospital, Airlangga University, Surabaya, Indonesia
2 Stem Cell Research And Development Center, Airlangga University, Surabaya, Indonesia
|Date of Submission||25-Apr-2020|
|Date of Decision||06-Jun-2020|
|Date of Acceptance||25-Aug-2020|
|Date of Web Publication||10-Oct-2020|
Dr. Ferdiansyah Mahyudin
Orthopedic and Traumatology Department, Faculty of Medicine, Dr. Soetomo General Hospital, Airlangga University, Surabaya 60132
Source of Support: None, Conflict of Interest: None
The advanced, metastasis, and reccurent of osteosarcoma (OS) patients have a poor prognosis postaggresive surgery and chemotherapy. Peripheral blood mononuclear cells (PBMCs) as cell-based immunotherapy may successful in the OS treatment. To investigate the enhancement apoptosis of OS-mesenchymal stem cells (OS-MSCs) co-cultivated with PBMCs sensitized using the secretome and granulocyte macrophage colony-stimulating factor (GMCSF). This true experimental study with posttest only control group design and in vitro study. The sample was cultured OS-MSCs which confirmed by Cluster of Differentiation-133 using immunocytochemistry (ICC) and histopathology analysis. The sample divided into six groups accordingly: OS-MSC, OS-MSC + PMBC, OS-MSC + PMBC + Secretome, OS-MSC + PMBC + GMCSF, OS-MSC + PBMC + Secretome + GMCSF (n = 5/N = 30). The enhancement of OS-MSCs apoptosis was analyzed through Interleukin-2 (IL-2) level through the Enyzme-Linked Immunosorbent Assay examination, expression of Signal Transducers and Activators of Transcription (STAT)-3 and caspase-3 by ICC. One-way analysis of variance test and Tukey Honestly Significant Difference to analyze the difference between the groups (P < 0.05). The highest of IL-2 level was found in the PBMC + Secretome + GMCSF group. The highest expression of caspase-3 was found in OS-MSC + PBMC + Secretome + GMCSF group with significant different between groups (P < 0.05). There was insignificant difference of STAT-3 epxression and IL-2 level between groups (P > 0.05). The co-cultivation of OS-MSCs and PBMSCs activated using secretome and GMCSF has a great ability to enhance OS-MSCs apoptosis.
Keywords: Granulocyte macrophage colony stimulating factor, mesenchymal stem cells, osteosarcoma, peripheral blood mononuclear cells, secretome
|How to cite this article:|
Mahyudin F, Yazid H, Edward M, Basuki MH, Bari YA, Rantam FA. The enhancement apoptosis of osteosarcoma mesenchymal stem cells co-cultivation with peripheral blood mononuclear cells sensitized by secretome and granulocyte macrophage colony-stimulating factor. J Adv Pharm Technol Res 2020;11:213-9
|How to cite this URL:|
Mahyudin F, Yazid H, Edward M, Basuki MH, Bari YA, Rantam FA. The enhancement apoptosis of osteosarcoma mesenchymal stem cells co-cultivation with peripheral blood mononuclear cells sensitized by secretome and granulocyte macrophage colony-stimulating factor. J Adv Pharm Technol Res [serial online] 2020 [cited 2022 Dec 1];11:213-9. Available from: https://www.japtr.org/text.asp?2020/11/4/213/297693
| Introduction|| |
Osteosarcoma (OS) is a malignant tumor with neoplastic cell producing bone that the most common primary sarcoma arises from the bone tissues. Treatment for the newly diagnosed OS including three main modalities: presurgical chemotherapy, surgical resection, and postsurgical chemotherapy that increased the outcome of localized OS cases. However, on the advanced, metastasic, and recurrent OS cases remain to have a poor prognosis. After treated aggressively by resection and chemotherapy, the 5-year survival rate on the localized OS about 65% and <20% for metastatic cases.
Recent treatment failure is related to the inability to target cancer stem cells due to capability of self-renewal, increase tumorigenicity, and chemotherapy resistance., Cell death resistance and immune screening avoidance are the two main mechanisms of tumor growth. Reinforcing and intensifying the cancer recognition by the immune system can improve the treatment efficacy. Formerly, necrosis was considered as the only cell death mechanism that affects the immune system and stimulates inflammatory response. Otherwise, apoptosis was considered as physiologic cell death pathway without immune stimulation. It is discovered that apoptotic cells were rapidly and specifically recognized by a phagocyte. Compared to classic apoptosis or immunogenic cell death can stimulate and intensify the immune system and response.,
Apoptosis occurs through caspase-dependent and caspase-independent pathways. The caspase-dependent pathway implicates the extrinsic and intrinsic factors. Activated cytokine receptors on the membrane cancer cells will induce Janus Kinase (JAK) and Signal Transducers and Activators of Transcription (STAT-3 and STAT-5). Those activations detain Bcl-xL and activate the Cytochrome-C. Subsequently, apoptotic protease activating factor-1 (APAF-1) will be increased then activate caspase-9 and stimulate caspase-3 that lead to apoptosis of OS cells.,
Nowadays, cell and antibody-based immunotherapy have gained success in childhood cancer management. Peripheral blood mononuclear cells (PBMCs) that considered superior to other cell-based treatment sources due to isolation process is less invasive compared to bone marrow. Moreover, autologous PBMCs administration does not need long-term immunosuppressive treatment and can be performed without ethical problem.,
Granulocyte-macrophage colony-stimulating factor (GMCSF) is a potent cytokine on stimulating the differentiation of myeloid cells. Furthermore, GMCSF has a role as an additional immune stimulus to generate anti-tumoral immunity. GMCSF also plays an important task in dendritic cells differentiation.,
The other new treatment modality is stem cell-based application, such as mesenchymal stem cells (MSCs) secretome. Secretome application is also considered safer due to containing no cellular element that makes it is less possibility of mutation and transforms into cancer-associated fibroblast within cancer microenvironment.,,
GMCSF, as well as secretome, will increase PBMCs immunogenicity by inducing it's containing immune cells. Thus, The aim of this study is to investigate the enhancement apoptosis of OS-MSCs cultivated with PBMCs activated by secretome and GMCSF sensitization in vitro.
| Subject and Methods|| |
Isolation, expansion, and culture of osteosarcoma mesenchymal stem cells
OS tissues were obtained from an open biopsy of patient at Orthopaedic Department Dr. Soetomo General Hospital Surabaya. Patient was confirmed and filled the written informed consent. The tissues firstly were confirmed as OS by histopathology. The tissues were washed by phosphate-buffered saline (PBS) (Sigma Aldrich, US) containing 5% penicillin/streptomycin (Gibco, US). Tissue samples were sliced using a scissor then put into Erlenmeyer tube with 5 ml Type I collagenase 0.075% within PBS containing 2% of penicillin/streptomycin. Samples were stirred with a magnetic stirrer for 30 min on 37°C temperature. Then 5 ml of α-minimal essential medium (Gibco, US) containing 20% heat-inactivated fetal bovine serum (Gibco, US) were added into the tube to neutralize the Type I collagenase activity. Samples were filtered afterward by pouring in beaker glass covered by 3 layers of sterile gauze. The supernatant of the filtration was centrifuged 2000 rpm in 5 min, disposed, and resuspensioned of the pellet by adding PBS. Centrifugation was repeated and disposed off again the supernatant remaining the pellet. This pellet then be resuspensioned within the complete medium. Those suspensions were cultivated on the culture plate and kept on the incubator 37°C, 5% CO2.
Isolation of peripheral blood mononuclear cells
The peripheral blood sample was collected from a healthy volunteer that had been screened for HIV and Hepatitis-B. The blood sample was slowly poured into conical tube 50cc and added with PBS (ratio 1:1) until homogenous suspensions then were slowly poured through the wall of conical containing Ficol 5cc and centrifuged 1600 rpm for 30 min in 26°C. After separated into 4 layers, the second layer with buffy coat form was slowly poured into the conical tube and washed using PBS 10cc. Subsequently, the conical was centrifuged 1600 rpm for 5 min. The pellet then was cultured in the medium.,
Sensitization of peripheral blood mononuclear cells
PBMCs suspension was divided into 4 groups that would be the control group, sensitized with secretome, sensitized with GMCSF, also the combination of secretome and GMCSF (ratio 1:1:1). All groups then were incubated in 37°C for 2 h.
Co-cultivation of osteosarcoma-mesenchymal stem cells with peripheral blood mononuclear cells
OS-MSCs monolayer cells were trypsinized as done until being a single cell. OS-MSCs then were put into coverslip within M24 until 5.104 cells. The cells were incubated in 37°C temperature and CO25% for 24 h. PBMCs sensitized with secretome, GMCSF, and those combinations then were added into each coverslip according to the classified group with ratio 1:1. All of the samples then were incubated in 37°C temperature and CO25% for 48 h.
Enyzme linked immunosorbent assay, immunocytochemistry, and immunohistochemistry analysis
Enyzme Linked Immunosorbent Assay (ELISA) model was used to measure Interleukin-2 (IL-2) level was sandwich ELISA Elabscience (E-EL-H0099). Immunocytochemistry was used to evaluate Cluster of Differentiation (CD)-133 and STAT-3 expressions using a fluorescent microscope. Caspase-3 expressions were evaluated using immunohistochemistry analysis.
One-way analysis of variance test and Tukey Honestly Significant Difference was used to evaluate differences between groups (P < 0.05).
| Results|| |
The histopathological examination confirmed the OS chondroblastic type [Figure 1]a. Positive expression result of CD-133 was detected [Figure 1]b.
|Figure 1: (a) Histopathological examination showed chondroblastic type osteosarcoma tissue (b) Cluster of Differentiation-133 marker results show positive immunocytofluorescence with magnification ×200|
Click here to view
The highest level IL-2 results were obtained for PBMCs that sensitized by secretome and GMCSF. Nonsensitized PBMCs as the control group had the lowest levels of IL-2 secretion [Table 1]. The PBMCs culture and results IL-2 level in PBMCs after sensitization in [Figure 2]a and [Figure 2]b.
|Table 1: The interleukin-2 level in peripheral blood mononuclear cells sensitized by secretome, granulocyte macrophage colony stimulating factor and combination|
Click here to view
|Figure 2: (a) Cultured peripheral blood mononuclear cells in each group with ×200 magnification (b) the Interleukin-2 level of peripheral blood mononuclear cells sensitized by secretome, granulocyte macrophage colony stimulating factor, and combination|
Click here to view
Microscopic evaluation of cultivation from between groups can be seen in [Figure 3]a OS-MSCs cultivation; 3b OS-MSCs and pure PBMCs cultivation; 3c co-cultivation of OS-MSCs and PBMCs sensitized with secretome; 3d OS-MSCs co-cultivated with PBMCs activated by GMCSF; 3e Co-cultivation of OS-MSCs and PBMCs activated by GMCSF and secretome. The greatest IL-2 level was found in OS-MSCs + PBMC + Secretome group [Table 2]. There was no significant different of IL-2 level between groups [Figure 3]f.
|Figure 3: Microscopic evaluation of cultivation (a) osteosarcoma-Mesenchymal stem cells only (b) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells (c) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cell sensitized with secretome (d) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cell sensitized with granulocyte macrophage colony stimulating factor (e) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cell activated using granulocyte macrophage colony stimulating factor and secretome (f) Interleukin-2 levels in osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by secretome, granulocyte macrophage colony stimulating factor, and combination|
Click here to view
|Table 2: Interleukin-2 level in osteosarcoma -mesenchymal stem cells co-cultivated with peripheral blood mononuclear cells sensitized by secretrome, Granulocyte macrophage colony stimulating factor and combination|
Click here to view
The STAT-3 expression as shown in [Figure 4]a OS-MSCs Cultivation; 4b OS-MSCs and PBMCs Cultivation sensitized with secretome; 4c OS-MSCs cultivation and PBMCs sensitized with GMCSF; 4d The OS-MSCs co-cultivated with PBMCs activated by GMCSF and secretome; The greatest expression of STAT-3 was found in OS + PBMC + GMCSF group [Table 3]. There was no significant different of STAT-3 expression between groups [Figure 4]e.
|Figure 4: The positive expression number of Signal Transducers and Activators of Transcription-3 (a) osteosarcoma-Mesenchymal stem cells only, (b) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by secretome (c) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by granulocyte macrophage colony stimulating factor (d) osteosarcoma-Mesenchymal stem cells cultivated with Peripheral blood mononuclear cells activated using granulocyte macrophage colony stimulating factor and secretome (e) Signal Transducers and Activators of Transcription-3 expressions in osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by secretome, granulocyte macrophage colony stimulating factor, and combination|
Click here to view
|Table 3: Signal transducers and activators of transcription-3 expression in osteosarcoma -mesenchymal stem cells co-cultivated with peripheral blood mononuclear cells sensitized by secretrome, granulocyte macrophage colony stimulating factor and combination|
Click here to view
The caspase-3 expression as shown in [Figure 5]a OS-MSCs only; 5b OS-MSCs co-cultivated with PBMCs sensitized by secretome; 5c OS-MSCs cultivated with PBMCs sensitized by GMCSF; 5d OS-MSCs co-cultivated with PBMCs activated by GMCSF and secretome. The greatest expression of Caspase-3 was found in OS-MSCs + PBMC + Secretome + GMCSF group [Table 4]. There was significant different of Caspase-3 expression between groups [Figure 5]e.
|Figure 5: The positive expression of caspase-3 in (a) osteosarcoma-Mesenchymal stem cells only, (b) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by secretome (c) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by granulocyte macrophage colony stimulating factor (d) osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells activated using granulocyte macrophage colony stimulating factor and secretome (e) The caspase-3 epression in osteosarcoma-Mesenchymal stem cells co-cultivated with Peripheral blood mononuclear cells sensitized by secretome, granulocyte macrophage colony stimulating factor, and combination|
Click here to view
|Table 4: Caspase-3 expression in Osteosarcoma -mesenchymal stem cells co-cultivated with peripheral blood mononuclear cells sensitized by secretrome, Granulocyte macrophage colony stimulating factor and combination|
Click here to view
| Discussion|| |
In this study, isolation of OS-MSCs was obtained from an open biopsy sample of an OS patient that have been histopathologically confirmed through CD-113 marker.,, Most PBMC's is found as naïve cells which possess no function as the effector., Sensitized PBMC's with secretome and GMCSF before co-cultivation with OS-MSCs hopefully able to increase the potential of PBMCs. PBMCs sensitized with secretome and GMCSF showed a higher amount of secreted IL-2 compared to all the groups. The amount of IL-2 level reflects the capability of PBMCs as immunotherapy agent. IL-2 may act directly as a cytokine which trigger the apoptotic process while also activate Natural killer-Cell which is a crucial cellular immunity in againts cancerous cells.
The expression of STAT-3 and the level of IL-2 showed insignificant result. However, caspase-3 expression in this study showed significant results regarding the superiority of apoptotic potential in OS-MSCs cultivated with PBMCs activated using GMCSF and secretome. Caspase-3 expression is heavily associated with the process of cell apoptosis through the dependent caspase pathway given its role as an effector component in the final stages of apoptosis. PBMCs that were sensitized with secretome and GMCSF have the highest apoptotic triggers potential in co-cultivation with OS-MSCs; and PBMCs that are sensitized with GMCSF alone can be an alternative to be the choice of immune-based therapy regimens for OS.
The GMCSF has a role in the differentiation, maturation, and activation of the PBMCs component in anti-cancer management. In addition, secretome can modulate lymphocyte proliferation and resemble the role of MSCs in the treatment of several diseases., However, if used separately, PBMCs sensitization with GMCSF has statistically better results than sensitization with secretome in caspase-3 expression as the originator of apoptosis OS-MSCs.
This study investigates OS-MSCs apoptosis by the evaluation of intrinsic pathway components including IL-2, STAT-3, and caspase-3 through a process in the mitochondria., The process was initiated by IL-2 in cytokine receptors that activate JAK and STAT-3 and STAT-5. This activation will inhibit the function of Bcl-xL and stimulate Cytochrome-C activation that increase in APAF-1 triggers caspase-9 activation and caspase-3 stimulation resulted in OS stem cell apoptosis. The ability to enhance the apoptosis of OS-MSCs through co-cultivation with PBMCs activated using secretome and GMCSF can be the basis of therapy with less immunological impact compared to chemotherapy.
| Conclusion|| |
OS-MSCs co-cultivated with PBMCs activated using by secretome and GMCSF has the greater ability enhancing OS-MSCs apoptosis. The further investigation before clinical trial on human is necessary.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, et al
. Osteosarcoma: Cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int 2016;2016:3631764.
Wang Z, Li B, Ren Y, Ye Z. T-cell-based immunotherapy for osteosarcoma: Challenges and opportunities. Front Immunol 2016;7:353.
Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther 2016;3:221-43.
Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, et al
. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015;20:495-514.
Montico B, Nigro A, Casolaro V, Dal Col J. Immunogenic apoptosis as a novel tool for anticancer vaccine development. Int J Mol Sci 2018;19:594.
Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: More than a marker for cytotoxicity? Front Immunol 2017;8:892.
Nagata S. Apoptosis and clearance of apoptotic cells. Annu Rev Immunol 2018;36:489-517.
Fortin A, Cregan SP, MacLaurin JG, Kushwaha N, Hickman ES, Thompson CS, et al
. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J Cell Biol 2001;155:207-16.
Zhang M, Huang B. The multi-differentiation potential of peripheral blood mononuclear cells. Stem Cell Res Ther 2012;3:48.
Koek WN, van der Eerden BC, Alves RD, van Driel M, Schreuders-Koedam M, Zillikens MC, et al
. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis. Bone 2017;95:108-14.
Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 2017;9:347-60.
Shiomi A, Usui T. Pivotal Roles of GMCSF in Autoimmunity and Inflammation. Mediators of Inflammation; 2015. p. 2015.
Vieira de Castro J, Gomes ED, Granja S, Anjo SI, Baltazar F, Manadas B, et al
. Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology. J Transl Med 2017;15:200.
Purnamawati P, Pawitan JA, Rachman A, Wanandi SI. Effects of umbilical cord-and adipose-derived stem cell secretomes on ALDH1A3 expression and autocrine TGF-β1 signaling in human breast cancer stem cells. F1000 Research 2018;7:249.
Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: Toward Cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 2017;18:E1852.
Hartwig S, Raschke S, Knebel B, Scheler M, Irmler M, Passlack W, et al
. Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014;1844:1011-7.
Rantam FA, Ferdiansyah, Nasronudin, Purwati. Stem cell exploration. Surabaya: Airlangga University Press; 2009. p. 70-5.
Riedhammer C, Halbritter D, Weissert R. Peripheral blood mononuclear cells: isolation, freezing, thawing, and culture. Methods Mol Biol 2016;1304:53-61.
Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett 2017;386:189-95.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol 2015;33:3029-35.
Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, et al
. CD133 expression in osteosarcoma and derivation of CD133+
cells. Mol Med Rep 2013;7:577-84.
Kleiveland CR. Peripheral blood mononuclear cells. In: Verhoeckx K, Cotter P, Lopez-Exposito I, Kleiveland C, Lea T, Mackie A, et al
. editors. The Impact of Food Bioactives on Health. Cham(CH): Springer; 2015. p. 161-7.
Guma SR, Lee DA, Ling Y, Gordon N, Kleinerman ES. Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer 2014;61:1362-8.
Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2014;2:11.
Chen J, Sun MX, Hua YQ, Cai ZD. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: A meta-analysis. J Cancer Res Clin Oncol 2014;140:1205-10.
Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics 2010;73:2291-305.
Levy DE, Lee CK. What does STAT3 Do? J Clin Invest 2002;109:1143-8.
Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
Khan S, Ahmad K, Alshammari EM, Adnan M, Baig MH, Lohani M, et al
. Implication of caspase-3 as a common therapeutic target for multineurodegenerative disorders and its inhibition using nonpeptidyl natural compounds. Biomed Res Int 2015;2015:379817.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment
| ||Marina Pierrevelcin, Vincent Flacher, Christopher G. Mueller, Romain Vauchelles, Eric Guerin, Benoît Lhermitte, Erwan Pencreach, Andreas Reisch, Quentin Muller, Layal Doumard, Wacym Boufenghour, Andrey S. Klymchenko, Sophie Foppolo, Charlotte Nazon, Noelle Weingertner, Sophie Martin, Claire Briandet, Véronique Laithier, Antonio Di Marco, Laurent Bund, Adeline Obrecht, Pascal Villa, Monique Dontenwill, Natacha Entz-Werlé |
| ||Advanced Healthcare Materials. 2022; : 2200195 |
|[Pubmed] | [DOI]|
||The Escalation of Osteosarcoma Stem Cells Apoptosis After the Co-Cultivation of Peripheral Blood Mononuclear Cells Sensitized with Mesenchymal Stem Cells Secretome and Colony Stimulating Factor-2 in vitro
| ||Ferdiansyah Mahyudin,Fachrizal Arfani Prawiragara,Mouli Edward,Dwikora Novembri Utomo,Mohammad Hardian Basuki,Yunus Abdul Bari,Alexander Patera Nugraha,Fedik Abdul Rantam |
| ||Journal of Blood Medicine. 2021; Volume 12: 601 |
|[Pubmed] | [DOI]|